D
Dominic Suarez
Researcher at GlaxoSmithKline
Publications - 10
Citations - 522
Dominic Suarez is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Small molecule & Demethylase. The author has an hindex of 5, co-authored 9 publications receiving 457 citations.
Papers
More filters
Journal ArticleDOI
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
Sharad K. Verma,Xinrong Tian,Louis V. LaFrance,Celine Duquenne,Dominic Suarez,Kenneth A. Newlander,Stuart Paul Romeril,Joelle Lorraine Burgess,Seth W. Grant,Brackley James,Alan P. Graves,Daryl A. Scherzer,Art Shu,Christine Thompson,Heidi M. Ott,Glenn S. Van Aller,Carl A. Machutta,Elsie Diaz,Yong Jiang,Johnson Neil W,Steven D. Knight,Ryan G. Kruger,Michael T. McCabe,Dashyant Dhanak,Peter J. Tummino,Caretha L. Creasy,William H. Miller +26 more
TL;DR: This work has identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 and GSK343, which are small molecule chemical tools that would be useful to further explore the biology of EZh2.
Patent
Cyclopropylamines as lsd1 inhibitors
TL;DR: In this article, the use of cyclopropylamine derivatives for modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1), was described.
Journal ArticleDOI
Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors.
Krista B. Goodman,Michael Jonathan Bury,Mui Cheung,Maria Cichy-Knight,Sarah E. Dowdell,Allison K. Dunn,Dennis Lee,Jeffrey A. Lieby,Michael L. Moore,Daryl A. Scherzer,Deyou Sha,Dominic Suarez,Dennis Murphy,Mark R. Harpel,Eric S. Manas,Dean E. McNulty,Roland S. Annan,Rosalie Matico,Benjamin K. Schwartz,John J. Trill,Thomas D. Sweitzer,Da-Yuan Wang,Paul M. Keller,John A. Krawiec,Michael Jaye +24 more
TL;DR: Sulfonylfuran urea 1 was identified in a high-throughput screening campaign as a potent and non-selective EL inhibitor, and modifications leading to improved LPL selectivity were identified.
Journal ArticleDOI
Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia
Ryan G. Kruger,Helai P. Mohammad,Kimberly N. Smitheman,Monica Cusan,Yan Liu,Melissa B. Pappalardi,Kelly Federowicz,Glenn S. Van Aller,Kasparec Jiri,Xinrong Tian,Dominic Suarez,Rouse Meagan B,Jessica L. Schneck,Jeffrey D. Carson,Patrick McDevitt,Thau F. Ho,Charles F. McHugh,William H. Miller,Johnson Neil W,Scott A. Armstrong,Peter J. Tummino +20 more
TL;DR: The anti-tumor effects of a novel LSD1 inhibitor (GSK2879552) in AML are described and pharmacological inhibition of LSD1 may provide a promising treatment for AML by promoting differentiation and subsequent growth inhibition of AML blasts.
Proceedings ArticleDOI
Abstract 3513: Inhibition of LSD1 for the treatment of cancer
Kimberly N. Smitheman,Monica Cusan,Yan Liu,Michael Butticello,Melissa B. Pappalardi,James J. Foley,Kelly Federowicz,Glenn S. Van Aller,Kasparec Jiri,Xinrong Tian,Dominic Suarez,Jess Schneck,Jeffrey D. Carson,Patrick McDevitt,Thau F. Ho,Charles F. McHugh,William H. Miller,Scott A. Armstrong,Christine L. Hann,Johnson Neil W,Ryan G. Kruger,Helai P. Mohammad,Shekhar Kamat +22 more
TL;DR: The anti-tumor effects of a novel, irreversible, GSK LSD1 inhibitor (GSK2879552) in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) are described and pharmacological inhibition of LSD1 may provide a promising treatment for AML and SCLC.